Get started
Author

Julia Ma

Observed name: Ma, Julia
OpenAlex ID: A5003304814
Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial
2023 · Richard B. Lipton, Rashmi B. Halker Singh, et al. · Cephalalgia · 16
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
2024 · Paul Rizzoli, Michael J. Marmura, et al. · The Journal of Headache and Pain · 10
PDF
The Current Landscape of HTA Framework and Key Challenges
2025 · Min-Hua Jen, Shahrul Mt-Isa, et al. · Statistics in Biopharmaceutical Research · 3
But We Do Not Have a Critical Care Cardiologist?
2025 · Subaina Khalid, Julia Ma, et al. · JACC Advances · 3
Improvement in Patient-Reported Outcomes When Ubrogepant Is Administered During the Migraine Prodrome (Premonitory Phase): Results From the PRODROME Trial (P9-12.001)
2023 · Richard B. Lipton, Andrea Harriott, et al. · Neurology · 2
Post-hoc Analysis of Safety in Phase 3 Atogepant ADVANCE Trial Participants with or without Cardiovascular Disease Risk Factors (P2-2.005)
2022 · Andrew Blumenfeld, Susan Hutchinson, et al. · Neurology · 2
Within-Person Analysis of Ubrogepant Treatment of Mild Versus Moderate-Severe Headache Pain during a Phase 3 Long-Term Safety Extension Trial (S31.006)
2022 · Richard B. Lipton, David W. Dodick, et al. · Neurology · 2
A Landscape Assessment of Key Evidence Needs in Study Design and Statistical Methodologies for HTA Submissions
2025 · Cornelia Dunger-Baldauf, Min-Hua Jen, et al. · Statistics in Biopharmaceutical Research · 1
Decrease in Body Weight With Once-Daily Atogepant for the Preventive Treatment of Migraine: A Post Hoc Analysis (P1-2.002)
2022 · David W. Dodick, Deborah L. Hay, et al. · Neurology · 1
Reply
2025 · Subaina Khalid, Julia Ma, et al. · JACC Advances
Benefit-risk assesment of atogepant: A post hoc anlysis of the advance trial
2023 · Stephanie Nahas, Jessica Ailani, et al. · Journal of the Neurological Sciences
PDF
Benefit-Risk Assessment of Atogepant: A Post Hoc Analysis of the ADVANCE Trial (P12-12.001)
2023 · Stephanie Nahas, Jessica Ailani, et al. · Neurology
Use of Real-World Evidence in Health Technology Assessment Submissions
2023 · Yingyi Liu, Julia Ma · Springer eBooks
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis (S31.008)
2022 · David W. Dodick, Richard B. Lipton, et al. · Neurology
Works count: 16
Citation count: 40
H-index: 3
I10-index: 2
Year
Topic
Type